Bison Ventures

Bison Ventures, established in 2021 and based in Seattle, Washington, is a venture capital firm that invests in early-stage technology companies. It focuses on frontier technologies that aim to improve human health and the environment. The firm collaborates with entrepreneurs who leverage innovative research and technology in their ventures. Bison Ventures is a Registered Investment Adviser.

Tom Biegala

Founding Partner

8 past transactions

Frontera Health

Seed Round in 2025
Frontera Health is changing autism care in underprivileged regions with AI-powered tools that assist physicians in evaluating and treating children with autism and related diseases.

Bonsai Robotics

Series A in 2025
Bonsai Robotics is a company based in San Jose, California, that specializes in vision-based automation solutions for off-road vehicles, particularly in the agricultural sector. The company develops a machine navigation system that utilizes computer vision to enable robotic operation of multiple vehicles. This technology helps farmers enhance productivity and performance while reducing their dependence on labor. In addition to automation, Bonsai Robotics offers analytics and telematics services that assist growers in improving their operational efficiency and safety.

Cadstrom

Seed Round in 2024
Cadstrom is an automated intelligence platform focused on electronic hardware design verification. The company develops electronic design automation tools that facilitate the design and validation of printed circuit boards. By leveraging artificial intelligence, Cadstrom's tools provide features such as real-time collaboration, rule checking, image rendering, and project management. These capabilities enable electronics engineers and designers to streamline their engineering processes and reduce the frequency of project revisions.

Passkey

Seed Round in 2024
Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.

Collaborative Robotics

Series B in 2024
Collaborative Robotics is a team of innovators and builders redefining the future of human-robot interaction. A future in which robots are trustworthy extensions of the environment. They operate, adapt, and react in response.

Vivodyne

Seed Round in 2023
Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.

Allonnia

Series A in 2023
Allonnia LLC is a biotechnology company based in Boston, Massachusetts, founded in 2019, that specializes in waste remediation services. The company focuses on developing enzymes, proteins, and microbes that effectively degrade or metabolize environmental contaminants, facilitating the recovery and upcycling of valuable materials from waste. Allonnia aims to provide innovative solutions to pressing environmental challenges, including safer water and cleaner mining, while promoting sustainability. Their unique approach integrates biology with advanced technology to create systems that transform waste into useful resources. Allonnia's commitment to environmental stewardship and innovation has garnered industry recognition, positioning it as a leader in the field of biotechnology and waste management.

Vivodyne

Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.